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A bs tr ac t
Background
Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/
kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol 
levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and 
efficacy of 52 weeks of treatment with evolocumab.
Methods
We stratified patients with hyperlipidemia according to the risk categories outlined 
by the Adult Treatment Panel III of the National Cholesterol Education Program. On 
the basis of this classification, patients were started on background lipid-lowering 
therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin 
at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at 
a dose of 10 mg daily, for a run-in period of 4 to 12 weeks. Patients with an LDL 
cholesterol level of 75 mg per deciliter (1.9 mmol per liter) or higher were then 
randomly assigned in a 2:1 ratio to receive either evolocumab (420 mg) or placebo 
every 4 weeks. The primary end point was the percent change from baseline in LDL 
cholesterol, as measured by means of ultracentrifugation, at week 52.
Results
Among the 901 patients included in the primary analysis, the overall least-squares 
mean (±SE) reduction in LDL cholesterol from baseline in the evolocumab group, tak-
ing into account the change in the placebo group, was 57.0±2.1% (P<0.001). The mean 
reduction was 55.7±4.2% among patients who underwent background therapy with 
diet alone, 61.6±2.6% among those who received 10 mg of atorvastatin, 56.8±5.3% 
among those who received 80 mg of atorvastatin, and 48.5±5.2% among those who 
received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for 
all comparisons). Evolocumab treatment also significantly reduced levels of apo-
lipoprotein B, non–high-density lipoprotein cholesterol, lipoprotein(a), and triglycer-
ides. The most common adverse events were nasopharyngitis, upper respiratory tract 
infection, influenza, and back pain.
Conclusions
At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-
dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol 
levels in patients with a range of cardiovascular risks. (Funded by Amgen; DESCARTES 
ClinicalTrials.gov number, NCT01516879.)
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Proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that is pro-duced predominantly in the liver, is secreted 
into the plasma and plays a major role in regulating 
levels of low-density lipoprotein (LDL) cholesterol by 
binding to hepatic LDL receptors and promoting 
their degradation.1,2 In short-term (8-to-12-week), 
placebo-controlled, phase 2 trials, PCSK9 inhibi-
tors have been shown to significantly reduce 
LDL cholesterol levels.3-9 Four of these trials in-
volved the use of evolocumab (AMG 145), a fully 
human monoclonal PCSK9 antibody, and assessed 
different doses and regimens in diverse patient 
populations with varying lipid phenotypes, car-
diovascular disease risks, and baseline use of 
lipid-lowering therapy.3-6 A longer-term, open-label 
extension study involving 1104 patients from the 
phase 2 trials compared evolocumab adminis-
tered monthly (at a dose of 420 mg) plus stan-
dard medical care with standard medical care 
alone.10 In the Durable Effect of PCSK9  Antibody 
Compared with Placebo Study (DESCARTES), a 
randomized, double-blind, placebo-controlled, 
phase 3 trial, we compared evolocumab with 
placebo in patients with hyperlipidemia who re-
ceived the study drug for 52 weeks after a run-in 
period of 4 to 12 weeks of background lipid-
lowering therapy.
Me thods
Study Design and Oversight
This study was conducted at 88 centers in nine 
countries (for details, see the Supplementary Ap-
pendix, available with the full text of this article at 
NEJM.org). Amgen sponsored and designed the 
trial (the latter in collaboration with the last author) 
and was responsible for data collection and analy-
sis. Local institutional review boards approved the 
study protocol, which is available at NEJM.org. The 
first draft of the manuscript was written by the 
first and last authors, and Amgen provided edito-
rial assistance. All the coauthors participated in 
subsequent revisions of the manuscript. The aca-
demic authors had full access to the data and 
vouch for their accuracy and completeness, for 
the analyses as presented, and for the fidelity of 
the study to the trial protocol.
Patients
Patients were eligible for enrollment in the trial if 
they were adults 18 to 75 years of age with an LDL 
cholesterol level of 75 mg per deciliter (1.94 mmol 
per liter) or higher and a fasting triglyceride level 
of 400 mg per deciliter (4.52 mmol per liter) or 
lower. Exclusion criteria were heart failure, recent 
myocardial infarction, recent or planned revascu-
larization procedure, uncontrolled hypertension, 
hyperthyroidism or hypothyroidism, moderate-
to-severe renal dysfunction, and active liver dis-
ease or hepatic dysfunction. Full details of the 
trial inclusion and exclusion criteria are provided 
in the Supplementary Appendix. All patients pro-
vided written informed consent before entering 
the trial.
Study Procedures
Patients who met eligibility criteria and, after re-
ceiving a 6-ml test placebo injection, agreed to 
undergo a regimen of monthly subcutaneous in-
jections for a year entered a run-in period of 4 to 
12 weeks, during which open-label background 
lipid-lowering therapy was administered (Fig. S1 
and S2 in the Supplementary Appendix). All pa-
tients were counseled on the components of the 
Therapeutic Lifestyle Changes diet, as outlined 
by the Adult Treatment Panel III (ATP III) of the 
National Cholesterol Education Program.11 On 
the basis of the screening LDL cholesterol level, 
previous use of statin therapy, and cardiovascular 
risk (as determined by the ATP-III guidelines), we 
assigned all patients to one of four lipid-lowering 
regimens: diet alone, diet with 10 mg of atorva-
statin daily, diet with 80 mg of atorvastatin daily, 
or diet with 80 mg of atorvastatin plus 10 mg of 
ezetimibe daily.
At the conclusion of the first 4 weeks of the 
run-in period, eligibility for randomization was 
based on a fasting LDL cholesterol level of 75 mg 
per deciliter or higher, as determined by the cen-
tral laboratory (for details, see the Supplementary 
Appendix). Among patients who met that crite-
rion, those with coronary heart disease (or a coro-
nary heart disease risk equivalent) who had an 
LDL cholesterol level of less than 100 mg per 
deciliter (2.59 mmol per liter) and those without 
coronary heart disease (or a coronary heart dis-
ease risk equivalent) who had an LDL cholesterol 
level of less than 130 mg per deciliter (3.36 mmol 
per liter) were eligible for randomization. Among 
patients in whom the lipid-lowering goal had not 
been reached, therapy was increased to the next 
level for an additional 4 weeks; the process was 
repeated a month later if the goal had still not 
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been reached. Patients who were receiving 80 mg 
of atorvastatin plus 10 mg of ezetimibe daily but 
whose LDL cholesterol level was still above the 
target value were eligible for randomization. 
Patients with an LDL cholesterol level of less than 
75 mg per deciliter were excluded, except for 
those who were receiving 80 mg of atorvastatin 
plus 10 mg of ezetimibe daily. These patients 
were allowed to discontinue ezetimibe and to 
participate in the study if the ATP-III goal was 
maintained after 4 weeks on the regimen of 
80 mg of atorvastatin daily.
After randomization, no changes to the as-
signed background lipid-lowering therapy were 
permitted. Randomization to the blinded phase 
of the trial, which was stratified according to 
background therapy, was performed centrally with 
the use of an interactive voice-response system. 
Patients were assigned in a 2:1 ratio to receive 
either 6 ml (420 mg) of evolocumab or placebo, 
administered subcutaneously every 4 weeks for 
48 weeks. The monthly injections could be split 
(e.g., two 3-ml doses or three 2-ml doses).
Study visits were scheduled every 4 weeks, 
with additional visits at weeks 13 and 37. Final 
administration of a study drug occurred at week 
48. Patients who discontinued a study drug for 
any reason were asked to continue all other 
study activities through week 52.
Efficacy and Safety End Points
The primary efficacy end point was the percent 
change from baseline in the LDL cholesterol level 
at week 52 in patients receiving evolocumab, as 
compared with the change in those receiving pla-
cebo. The primary efficacy end point was also 
assessed separately for each of the background-
therapy groups. Secondary efficacy end points 
included the absolute change from baseline in 
the LDL cholesterol level at week 52, the percent 
change from baseline in the LDL cholesterol at 
week 12, and the percentage of patients with an 
LDL cholesterol level of less than 70 mg per deci-
liter (1.81 mmol per liter) at week 52. Additional 
secondary end points included the percent change 
from baseline at week 52 in levels of total choles-
terol, high-density lipoprotein (HDL) cholesterol, 
non-HDL cholesterol, very-low-density lipoprotein 
(VLDL) cholesterol, and apolipoprotein B, the ra-
tio of total cholesterol to HDL cholesterol, the 
ratio of apolipoprotein B to apolipoprotein A1, 
and the levels of lipoprotein(a) and triglycerides.
We assessed the long-term consistency of the 
effect of evolocumab, as compared with placebo, 
by comparing the percent change in the LDL 
cholesterol level at week 12 with that at week 52. 
All lipid analyses were performed as described 
previously.5 All LDL cholesterol levels that were 
used as primary or secondary trial end points 
were measured by means of ultracentrifugation 
unless otherwise specified.12,13
Tertiary and exploratory end points are listed 
in the Supplementary Appendix. Long-term safety 
and side-effect profiles were assessed by means 
of adverse-event reporting, clinical examination, 
and laboratory testing. Anti-evolocumab anti-
bodies were assayed at baseline and at weeks 12, 
24, 36, and 52, as described previously.14
Statistical Analysis
We determined that with enrollment of 900 pa-
tients (600 in the evolocumab group and 300 in 
the placebo group) the study would have suffi-
cient power (>99%) to detect at least a 20% reduc-
tion in the LDL cholesterol level in the evolocu-
mab group, as compared with the placebo group, 
with a common standard deviation of 20%, after 
accounting for treatment attenuation and assum-
ing that 2% of the patients would not receive a 
study drug. All analyses included data from pa-
tients who received at least one dose of a study 
drug. We analyzed all primary and secondary ef-
ficacy end points on the basis of the randomized 
study-group assignments.
We used a repeated-measures linear-effects 
model to assess the primary end point. Included 
in this model were terms for the study group, 
background-therapy group, scheduled visit, and 
the interaction between the treatment and the 
scheduled visit (with the use of an unstructured 
covariance matrix). Missing values were not im-
puted. We used residual maximum likelihood as 
the method of estimation and the Kenward–
Roger method to estimate denominator degrees 
of freedom for the tests of fixed effects. Sensi-
tivity and nonparametric analyses as well as the 
analysis of covariance are described in the Sup-
plementary Appendix.
All other hypothesis testing was two-sided 
with a significance level of 0.05, with Hochberg 
adjustment used to control for multiple testing. 
All P values have been adjusted for multiple test-
ing unless otherwise specified. Key safety end 
points included adverse events occurring during 
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treatment, laboratory values, and the presence of 
anti-evolocumab antibodies. Safety analyses were 
conducted with the use of descriptive statistics 
that were based on observed data with no impu-
tation. Adverse events were coded with the use 




The study was conducted from January 2012 
through November 2013. Of the 2120 patients 
who were screened, 905 underwent randomiza-
tion, 901 received at least one dose of a study 
drug, and 800 (88.4%) completed 52 weeks of 
treatment (Fig. 1). Of the 901 patients who re-
ceived a study drug, 111 received background 
lipid-lowering therapy with diet alone, 383 received 
10 mg of atorvastatin daily, 218 received 80 mg 
of atorvastatin daily, and 189 received 80 mg of 
atorvastatin plus 10 mg of ezetimibe daily.
Baseline demographic and clinical variables 
are shown in Table 1, and baseline lipid values 
in Table 2; baseline apolipoprotein and PCSK9 
measures are shown in Tables S1 and S2 in the 
Supplementary Appendix. As would be antici-
pated, the prevalence of cardiovascular disease 
and of cardiovascular risk factors was higher in 
the groups receiving more intensive background 
lipid-lowering therapy (Table 1). The mean base-
line levels of unbound (free) PCSK9 were lowest 
in the diet-alone group and increased progres-
sively with the intensity of lipid-lowering thera-
py, as would be expected with statin treatment 
(Table S2 in the Supplementary Appendix).
Efficacy End Points
At 52 weeks, the least-squares mean (±SE) reduc-
tion in LDL cholesterol from baseline in the evo-
locumab group, taking into account the change 
in the placebo group, was 57.0±2.1% at week 52 
(Table 2) and 57.5±1.6% at week 12 (Fig. 2, and 
Fig. S3A in the Supplementary Appendix). In the 
analysis according to background-therapy group, 
the least-squares mean reduction in LDL choles-
terol in the evolocumab group, taking into ac-
count the change in the placebo group, was 
55.7±4.2% in the diet-alone group, 61.6±2.6% 
in the group receiving 10 mg of atorvastatin, 
56.8±5.3% in the group receiving 80 mg of ator-
vastatin, and 48.5±5.2% in the group receiving 
80 mg of atorvastatin plus 10 mg of ezetimibe 
(P<0.001 for all comparisons). The LDL choles-
terol level at baseline and the percent reductions 
from baseline that were calculated with the use 
of the Friedewald formula (Table S1 in the Sup-
plementary Appendix) were similar to those that 
were measured by means of ultracentrifugation. 
The level of LDL cholesterol was reduced below 
70 mg per deciliter in 82.3% of patients in the 
evolocumab group, as compared with 6.4% of 
those in the placebo group (Table 2).
Evolocumab treatment, as compared with pla-
cebo, also resulted in significant least-squares 
mean percent reductions from baseline in levels 
of apolipoprotein B, non-HDL cholesterol, lipo-
protein(a), and triglycerides (Table S1 in the Sup-
plementary Appendix). After taking into account 
the change in the placebo group, evolocumab 
treatment resulted in a least-squares mean in-
crease of 5.4±1.1% in the HDL cholesterol level 
(P<0.001) and of 3.0±0.8% in the apolipoprotein 
A1 level (unadjusted P<0.001). No meaningful 
changes were seen in levels of high-sensitivity 
C-reactive protein (Table S1 in the Supplemen-
tary Appendix).
In the evolocumab group, mean reductions 
from baseline in unbound PCSK9 levels that 
were measured at weeks 13 and 37 at an interval 
of 1 week after administration were 91.1±1.8% 
and 86.9±1.3%, respectively; in measurements 
performed at weeks 12, 24, 36, and 52 at an in-
terval of 4 weeks after administration, there 
were mean reductions of 41.2±1.2%, 38.3±2.2%, 
38.3±2.2%, and 42.4±1.8%, respectively (Table S2 
in the Supplementary Appendix). Reductions after 
1 week were consistently around 90% regardless 
of background therapy, but those at 4 weeks af-
ter drug administration were greater in the diet-
alone group and the group receiving 10 mg of 
atorvastatin than in the two groups receiving 
80 mg of atorvastatin (Table S2 and Fig. S4 and 
S5 in the Supplementary Appendix).
Figure 1 (facing page). Enrollment and Outcomes.
Patients were included in the safety and efficacy analy-
ses if they had the required data available for the result 
of interest. For example, for the primary end point, pa-
tients needed to have data for low-density lipoprotein 
cholesterol levels at baseline and at 52 weeks. Reasons 
for screening exclusions before the run-in period are 
not available.
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Adverse Events and Immunogenicity
The overall incidence of adverse events occurring 
during treatment was similar in the evolocumab 
group and the placebo group, with 448 of 599 pa-
tients (74.8%) and 224 of 302 patients (74.2%), 
respectively, having an adverse event. The most 
common adverse events in the evolocumab group 
were nasopharyngitis, upper respiratory tract in-
fection, influenza, and back pain (Table 3, and 
Table S3 in the Supplementary Appendix). Seri-
ous adverse events occurred in 33 patients (5.5%) 
in the evolocumab group and 13 patients (4.3%) 
in the placebo group (Table S4 in the Supplemen-
tary Appendix). Adverse events leading to the dis-
continuation of a study drug occurred in 13 patients 
(2.2%) in the evolocumab group and 3 patients 
(1.0%) in the placebo group (Table S5 in the Sup-
plementary Appendix). Injection-site reactions were 
reported in 34 patients (5.7%) in the evolocumab 
group and 15 patients (5.0%) in the placebo group, 
resulting in discontinuation of evolocumab in 1 pa-
tient (Table S6 in the Supplementary Appendix).
Elevations of creatine kinase levels to more 
than five times the upper limit of the normal 
range occurred in 7 patients (1.2%) in the evoloc-
u mab group and 1 patient (0.3%) in the placebo 
group, with myalgia reported by 24 patients 
(4.0%) and 9 patients (3.0%), respectively; eleva-
tions of aminotransferase levels to more than 
three times the upper limit of the normal range 
occurred in 5 patients (0.8%) and 3 patients 
(1.0%), respectively (Table 3). Evolocumab treat-
ment did not have an adverse effect on glycemic 
measures (Table 3). Two patients in the evo-
locumab group had detectable binding antibod-
ies before or at the time of randomization. One 
patient in the evolocumab group had newly de-
tected transient anti-evolocumab binding anti-
bodies during treatment. No anti-evolocumab 
neutralizing antibodies were detected in any pa-
tient (Table S7 in the Supplementary Appendix).
Discussion
We found that treatment with 420 mg of evo-
locumab every 4 weeks for 52 weeks resulted in a 
relative reduction in LDL cholesterol levels of 
57%, taking into account the change in the pla-
cebo group. This result was consistent with the 
effects that were observed with the same evoloc-
umab regimen in the 12-week phase 2 trials.3-6 
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number of patients (percent)
Patients with adverse event
Any 224 (74.2) 448 (74.8)
Serious 13 (4.3) 33 (5.5)
Leading to discontinuation of a study drug 3 (1.0) 13 (2.2)
Adjudicated atherosclerotic event 2 (0.7) 6 (1.0)
Death* 0 2 (0.3)
Common adverse events†
Nasopharyngitis 29 (9.6) 63 (10.5)
Upper respiratory tract infection 19 (6.3) 56 (9.3)
Influenza 19 (6.3) 45 (7.5)
Back pain 17 (5.6) 37 (6.2)
Bronchitis 14 (4.6) 27 (4.5)
Urinary tract infection 11 (3.6) 27 (4.5)
Cough 11 (3.6) 27 (4.5)
Arthralgia 14 (4.6) 25 (4.2)
Sinusitis 9 (3.0) 25 (4.2)
Headache 11 (3.6) 24 (4.0)
Myalgia 9 (3.0) 24 (4.0)
Dizziness 8 (2.6) 22 (3.7)
Nausea 10 (3.3) 20 (3.3)
Musculoskeletal pain 9 (3.0) 20 (3.3)
Hypertension 7 (2.3) 19 (3.2)
Diarrhea 8 (2.6) 18 (3.0)
Gastroenteritis 6 (2.0) 18 (3.0)
Injection-site erythema 6 (2.0) 16 (2.7)
Oropharyngeal pain 4 (1.3) 15 (2.5)
Muscle strain 10 (3.3) 14 (2.3)
Muscle spasm 8 (2.6) 14 (2.3)
Pain in extremity 13 (4.3) 13 (2.2)
Fatigue 9 (3.0) 13 (2.2)
Upper abdominal pain 2 (0.7) 13 (2.2)
Osteoarthritis 5 (1.7) 12 (2.0)
Vomiting 5 (1.7) 11 (1.8)
Viral upper respiratory tract infection 3 (1.0) 11 (1.8)
Dyspepsia 2 (0.7) 11 (1.8)
Rash 1 (0.3) 11 (1.8)
Nasal congestion 7 (2.3) 10 (1.7)
Cystitis 4 (1.3) 10 (1.7)
Tendonitis 3 (1.0) 10 (1.7)
Anxiety 2 (0.7) 10 (1.7)
Seasonal allergy 4 (1.3) 9 (1.5)
Neck pain 3 (1.0) 9 (1.5)
Insomnia 3 (1.0) 9 (1.5)
Pharyngitis 2 (0.7) 9 (1.5)
Arthropod bite 1 (0.3) 9 (1.5)
Gastroesophageal reflux disease 8 (2.6) 8 (1.3)
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number of patients (percent)
Contusion 5 (1.7) 8 (1.3)
Injection-site pain 4 (1.3) 8 (1.3)
Noncardiac chest pain 0 8 (1.3)
Injection-site bruising 6 (2.0) 7 (1.2)
Musculoskeletal chest pain 3 (1.0) 7 (1.2)
Abdominal pain 2 (0.7) 7 (1.2)
Palpitations 1 (0.3) 7 (1.2)
Anemia 0 7 (1.2)
Nephrolithiasis 0 7 (1.2)
Laceration 5 (1.7) 6 (1.0)
Gastritis 4 (1.3) 6 (1.0)
Migraine 3 (1.0) 6 (1.0)
Eczema 3 (1.0) 6 (1.0)
Angina pectoris 2 (0.7) 6 (1.0)
Ventricular extrasystoles 2 (0.7) 6 (1.0)
Constipation 2 (0.7) 6 (1.0)
Injection-site swelling 2 (0.7) 6 (1.0)
Pyrexia 1 (0.3) 6 (1.0)
Procedural pain 1 (0.3) 6 (1.0)
Vertigo 5 (1.7) 5 (0.8)
Asthma 4 (1.3) 5 (0.8)
Ligament pain 3 (1.0) 5 (0.8)
Arthritis 3 (1.0) 5 (0.8)
Fall 5 (1.7) 3 (0.5)
Pruritus 5 (1.7) 2 (0.3)
Foot fracture 5 (1.7) 1 (0.2)
Elevated alanine aminotransferase or 
aspartate aminotransferase‡
>3× ULN 3 (1.0) 5 (0.8)
>5× ULN 1 (0.3) 3 (0.5)
Elevated creatine kinase‡
>5× ULN 1 (0.3) 7 (1.2)
>10× ULN 1 (0.3) 3 (0.5)
Potential injection-site reaction§ 15 (5.0) 34 (5.7)
* The two deaths were from cardiac failure and myocardial infarction and are included as adjudicated atherosclerotic events.
† Listed are the preferred terms reported for at least 1% patients in either study group. For measures of glycemia, the mean 
(±SE) change from baseline for fasting glucose at week 52 was 1.3±0.7 mg per deciliter (0.07±0.04 mmol per liter) for evo-
locumab and 0.4±0.9 mg per deciliter (0.02±0.05 mmol per liter) for placebo. The mean change from baseline for glycated 
hemoglobin at week 52 was 0.02±0.02 percentage points for evolocumab and 0.00±0.03 percentage points for placebo.
‡ The elevated values relative to the upper limit of the normal range (ULN) were those that were recorded at any visit after baseline.
§ Potential events were identified by means of a broad-search strategy, in which event categories were defined with the use 
of preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA) and either standard MedDRA queries or 
internal groupings.
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cacy of evolocumab from week 12 to week 52. 
Our findings were also similar to the finding of 
a relative reduction of 52% in LDL cholesterol 
levels reported in the first year of the Open-Label 
Study of Long-Term Evaluation against LDL-C 
(OSLER) study.10
Our study design called for a run-in period in 
which background lipid-lowering therapy was 
adjusted on the basis of LDL cholesterol goals, 
according to the patient’s ATP-III–defined car-
diovascular risk. These risk-based lipid-lowering 
therapies ranged from diet alone to a combina-
tion of 80 mg of atorvastatin plus 10 mg of the 
cholesterol-absorption inhibitor ezetimibe daily. 
Percent reductions in LDL cholesterol in the evo-
locumab group, taking into account the change 
in the placebo group, differed slightly according 
to background therapy, ranging from 48.5% in 
the group receiving atorvastatin plus ezetimibe 
to 61.6% in the group receiving 10 mg of atorva-
statin.
Our findings provide some insights into the 
magnitude and duration of PCSK9 inhibition 
with antibodies as a function of background 
lipid-lowering therapy. In our study, unbound 
PCSK9 was measured at 1 week and at 4 weeks 
after the administration of evolocumab. The dif-
ferences in unbound PCSK9 among background-
therapy groups at 1 week were minimal, despite 
substantial differences in baseline levels, indi-
cating that virtually all PCSK9 is antibody-bound 
initially. However, not only were baseline levels 
of PCSK9 higher among patients receiving high-
dose atorvastatin than among patients in the 
other groups, but there also was a more rapid 
increase in PCSK9 levels 4 weeks after the ad-
ministration of each dose of evolocumab in 
these patients, suggesting that the rate of PCSK9 
production is increased in patients receiving in-
tensive statin therapy.
The effect on PCSK9 levels that we observed 
and the consequent reductions in LDL choles-
terol levels at 4 weeks after the administration of 
evolocumab were similar to those reported in 
patients receiving either 10 mg or 80 mg of ator-
vastatin plus another PCSK9 monoclonal antibody, 
alirocumab (at a dose of 150 mg), even though 
patients received alirocumab every 2 weeks rather 
than every 4 weeks.7 Thus, it may be that patients 
who have already been treated with high-dose 
statins or combination lipid-lowering therapy may 
have slightly less capacity to further up-regulate 
LDL-receptor activity with PCSK9 inhibition or 
may require higher doses of antibody. Our find-
ings are also in keeping with those of a number 
of other trials in which no synergism between 
statins and PCSK9 inhibition was observed. Al-
though statins up-regulate PCSK9, this does not 
explain why the reduction in LDL cholesterol 
levels that is associated with an initial dose of a 
statin is relatively large in comparison to the ad-
ditional 6% reduction observed when the statin 
dose is doubled. 
The recently published cholesterol guidelines 
of the American College of Cardiology and the 
American Heart Association (ACC–AHA)15 in-
clude several changes from the ATP-III guide-
lines published in 2002. Among these changes is 
the recommendation that the intensity of thera-
py be guided by cardiovascular risk rather than 
by LDL cholesterol goals. However, despite this 
recommendation, an LDL cholesterol level of less 
than 70 mg per deciliter remains a treatment 
target for patients at very high risk for cardiovas-
cular disease in many countries. In our study, 
this target was achieved in more than 80% of 
patients with the use of 420 mg of evolocumab 
every 4 weeks. In addition, there were signifi-
cant reductions in the levels of other athero-
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Figure 2. Percent Reduction from Baseline in Low-Density Lipoprotein (LDL) 
Cholesterol Levels in the Evolocumab Group, as Compared with the Placebo 
Group, at Weeks 12 and 52, According to Background Lipid-Lowering Therapy.
Values are means with lower 95% confidence limits (as indicated by T bars) in 
the active-treatment groups after taking into account the values in the placebo 
group. LDL cholesterol was measured by means of ultracentrifugation separation.
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including lipoprotein(a), and modest but signifi-
cant increases in levels of HDL cholesterol and 
apolipoprotein A1, similar to those reported with 
evolocumab previously.3-6,16
More patients in the evolocumab group than in 
the placebo group were reported to have serious 
adverse events during treatment and to have ad-
verse events leading to drug discontinuation. 
However, a review of the individual adverse events 
in these categories does not offer any clear indica-
tion of specific risks associated with evolocumab. 
The most common adverse events were nasophar-
yngitis, upper respiratory tract infection, influen-
za, and back pain, all of which occurred more 
frequently in the evolocumab group. There were 
more reports of myalgia and elevated creatine ki-
nase levels among patients receiving evolocumab.
In conclusion, among patients at risk for a 
wide range of coronary diseases who were re-
ceiving guideline-recommended background lipid-
lowering therapy, the monoclonal PCSK9 anti-
body evolocumab reduced LDL cholesterol levels 
by 57%, as compared with placebo, at 52 weeks.
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